Pro Medicus Ltd (ASX: PME) shares are in the spotlight on Wednesday.
In morning trade, the health imaging technology company's shares are down slightly to $297.47.
Image source: Getty Images
What's going on with Pro Medicus shares?
Investors have been selling the company's shares today after broad weakness in the tech sector offset the announcement of another contract win.
According to the release, the company has signed a five-year, $10 million Enterprise PACS deal at University Hospital Heidelberg (UKHD) and German Cancer Research Institute (DKFZ), and associated hospitals, Thoraxklink Heidelberg and KKH Bergstrasse.
The release notes that UKHD is one of Germany's largest and most renowned academic medical centres. It has approximately 2,600 beds and nearly 14,000 staff members.
In addition, UKHD is linked to the medical faculty of Heidelberg University, and is co-located and closely cooperates with DKFZ. It notes that together, they provide one of Europe's top centres for medical research and teaching.
Management also highlights that DKFZ is Germany's largest biomedical research institution, with over 3,400 employees from more than 90 nations, comprising approximately 1,490 scientists.
Furthermore, UKHD and DKFZ form the core of one of Europe's preeminent hubs for cancer research and treatment. As a result, they require the most advanced technology to support cutting-edge diagnostics, innovative treatment pathways and translational research. It points out that they rely on imaging not only for day-to-day patient care, but also to bridge the gap between scientific discovery and clinical application.
In light of this, it is no wonder they have signed a contract with Pro Medicus.
Its Visage 7 Enterprise Imaging Platform has ultrafast, highly scalable architecture, which enables seamless access to massive imaging datasets across institutions, specialties, and research domains. This makes it possible to consolidate disparate legacy systems, streamline workflows and provide clinicians with the tools they need to interpret even the most complex imaging studies with confidence and precision.
'A future-proof platform'
Commenting on the deal, Heidelberg University Hospital's chief information officer, Oliver Reinhard, said:
Imaging is at the heart of both patient care and research at University Hospital Heidelberg. With Visage 7, we are gaining a future-proof platform that can support our clinicians with the most advanced diagnostic tools, while enabling researchers to work seamlessly with imaging data at scale. This is essential for our mission to translate scientific discoveries rapidly into improved outcomes for patients.
Pro Medicus' chief technology officer of Visage Imaging, Malte Westerhoff, adds:
We are honoured to partner with UKHD and DKFZ, one of Europe's most important medical and cancer research centers. Visage 7 is uniquely positioned to deliver both the diagnostic performance and the research capabilities required by leading academic medical centers. Together, we are shaping the future of enterprise imaging and help empowering clinicians and researchers to deliver better care.
